Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review

Viruses(2024)10.3390/v16030399Source: DataRank Database

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review is a research paper published in Viruses (2024). On theSindex it has a DataRank of 0. It has been cited 56 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access56 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 17.15)OA: goldTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Kaiming Tao ORCID,Vinie Kouamou ORCID,Ava Avalos ORCID,Jake Scott ORCID,Philip Grant

Live enrichment

PubMed:38543764 PMC:PMC10975848 OpenAlex:https://openalex.org/W4392378382

National Institutes of Health

Grant: 2R24AI13661806

NIAID NIH HHS

Grant: R24 AI136618

FWCI

17.15

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1999-4915/16/3/399/pdf?version=1709552024

publisherhttps://www.mdpi.com/1999-4915/16/3/399/pdf?version=1709552024

publisherhttps://www.mdpi.com/1999-4915/16/3/399/pdf

journalhttps://doi.org/10.3390/v16030399

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38543764

Fields of Study

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV-related health complications and treatmentsHumansCross-Sectional StudiesPrevalenceLamivudineHIV InfectionsHeterocyclic Compounds, 3-RingMutationHIV Integrase InhibitorsAnti-HIV AgentsOxazinesPiperazinesPyridonesDolutegravir

MeSH Terms

DolutegravirCross-Sectional StudiesHeterocyclic Compounds, 3-RingHumansMutationOxazinesPiperazinesPyridonesHIV InfectionsPrevalenceLamivudineAnti-HIV AgentsHIV Integrase Inhibitors

Keywords

DolutegravirMedicineTolerabilityClinical trialRegimenHuman immunodeficiency virus (HIV)Antiretroviral therapyIntegrase inhibitorIntegraseInternal medicineCohortHIV drug resistanceViral loadAdverse effectVirologyHIVTreatmentSystematic reviewepidemiology

Sustainable Development Goals

SDG 0: Good health and well-being